2FPZ
Human tryptase with 2-amino benzimidazole
Summary for 2FPZ
Entry DOI | 10.2210/pdb2fpz/pdb |
Descriptor | Tryptase beta-2, 2H-BENZOIMIDAZOL-2-YLAMINE (3 entities in total) |
Functional Keywords | serine protease, drug design, hydrolase |
Biological source | Homo sapiens (human) |
Cellular location | Secreted: P20231 |
Total number of polymer chains | 4 |
Total formula weight | 110498.31 |
Authors | Somoza, J.R. (deposition date: 2006-01-17, release date: 2006-03-07, Last modification date: 2011-07-13) |
Primary citation | McGrath, M.E.,Sprengeler, P.A.,Hirschbein, B.,Somoza, J.R.,Lehoux, I.,Janc, J.W.,Gjerstad, E.,Graupe, M.,Estiarte, A.,Venkataramani, C.,Liu, Y.,Yee, R.,Ho, J.D.,Green, M.J.,Lee, C.-S.,Liu, L.,Tai, V.,Spencer, J.,Sperandio, D.,Katz, B.A. Structure-guided design of Peptide-based tryptase inhibitors. Biochemistry, 45:5964-5973, 2006 Cited by PubMed Abstract: Improved peptide-based inhibitors of human beta tryptase were discovered using information gleaned from tripeptide library screening and structure-guided design methods, including fragment screening. Our efforts sought to improve this class of inhibitors by replacing the traditional Lys or Arg P1 element. The optimized compounds display low nanomolar potency against the mast cell target and several hundred-fold selectivity with respect to serine protease off targets. Thus, replacement of Lys/Arg at P1 in a peptide-like scaffold does not need to be accompanied by a loss in target affinity. PubMed: 16681368DOI: 10.1021/bi060173m PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2 Å) |
Structure validation
Download full validation report